BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia

BioNexus Gene Lab Corp

BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.
VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.
Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.
Conditions include IP license agreement; other definitive agreements not yet executed.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

BioNexus Gene Lab Corp issued restricted shares representing 19.9% of its outstanding common stock of common stock to Fidelion Diagnostics Pte. Ltd..

Security: common stock
Shares: restricted shares representing 19.9% of its outstanding common stock
Purchaser: Fidelion Diagnostics Pte. Ltd.

Exact text from the filing

In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares.

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-008044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.